Spectral AI Inc (NASDAQ:MDAI) said it has appointed Jeremiah Sparks as Chief Commercialization Officer.
Sparks will spearhead the domestic and international commercialization of Spectral AI's flagship product, DeepView.
With over 20 years of experience in medical device marketing, including global strategy and market assessment, Sparks brings a wealth of expertise to Spectral AI. His experience includes driving market assessments, developing commercialization plans, and increasing return on investment for various MedTech companies through strategic marketing approaches.
In particular, Sparks has a history of successfully launching new products on national and global scales, having worked with industry giants such as Johnson & Johnson (NYSE:JNJ), Healthpoint, and Allergan (NYSE:AGN).
“We are thrilled to have Jeremiah join the company as we move towards commercialization of DeepView,” said Peter Carlson, CEO of Spectral AI.
“With his strong track record, most recently as Vice President of Global Strategy at AVITA Medical, he will hit the ground running as we drive market entry of Spectral AI’s products, allowing our innovative wound management solutions to reach physicians and the patients for whom they provide essential care.”
“My previous roles have me well poised to bring Spectral AI's technology to market across a broad range of locations, demographics and clinical indications,” Sparks added.
"This groundbreaking technology holds promise for several applications and I am excited to help the team deliver this advancement in wound care management to as many patients as possible."
Sparks holds an MBA from Thunderbird Graduate School of Global Management and a Bachelor's degree in International Relations from Brigham Young University. Throughout his career, he has authored multiple publications focused on health economics, cost-effectiveness, and outcomes research, emphasizing real-world evidence.